|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Associating liver partition and portal vein ligation for staged hepatectomy: the current role and development显示文摘BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy(ALPPS) has recently been developed to induce rapid liver hypertrophy and reduce posthepatectomy liver failure in patients with insufficient future liver remnant(FLR). ALPPS is still considered to be in an early developmental phase because surgical indications and techniques have not been standardized. This article aimed to review the current role and future developments of ALPPS.DATA SOURCES: Studies were identified by searching MEDLINE and Pub Med for articles from January 2007 to October 2016 using the keywords 'associating liver partition and portal vein ligation for staged hepatectomy' and 'ALPPS'. Additional papers were identified by a manual search of references from key articles.RESULTS: ALPPS induces more hypertrophy of the FLR in less time than portal vein embolization or portal vein ligation.The benefits of ALPPS include rapid hypertrophy 47%-110% of the liver over a median of 6-16.4 days, and 95%-100% completion rate of the second stage of ALPPS. The main criticisms of ALPPS are centered on its high morbidity and mortality rates. Morbidity rates after ALPPS have been reported to be 15.3%-100%, with ≥ the Clavien-Dindo grade III morbidity of 13.6%-44%. Mortality rates have been reported to be 0%-29%.The important questions to ask even if oncologic long-term results are acceptable are: whether the gain in quality and quantity of life can be off balance by the substantial risks of morbidity and mortality, and whether stimulation of rapid liver hypertrophy also accelerates rapid tumor progression and spread. Up till now, the documentations of the ALPPS procedure come mainly from case series, and most of these series include heterogeneous groups of malignancies. The numbers are also too small to separately evaluate survival for different tumor etiologies.CONCLUSIONS: Currently, knowledge on ALPPS is limited, and prospective randomized studies are lacking. From the reported preliminary results, safety of the ALPPS procedure remains questionable. ALPPS should only be used in experienced, high-volume hepatobiliary centers. | Wan Yee Lau Eric CH Lai Stephanie HY Lau | 2017 | Hepatobiliary & Pancreatic Diseases International2017，16，1： | 16 |
| 2 | Current therapy of hilar cholangiocarcinoma显示文摘BACKGROUND: Hilar cholangiocarcinoma (HC) is an adeno-carcinoma of the extrahepatic biliary tree arising from the main left or right hepatic ducts or their confluence. This tumor is still considered to be difficult to treat or to cure. DATA SOURCES: We reviewed the medical literature on HC. Relevant and updated information on this tumor was analyzed in a concise and easy-to-read manner. The article is not intended to be a systematic review, but an extensive search was conducted on PubMed and MEDLINE using the keywords 'hilar cholangiocarcinoma' and 'Klatskin tumor' until July 2011. RESULTS: The selection and the timing of management options for patients with HC are determined by the degree of certainty of the diagnosis, the general condition of the patients, the underlying liver function and the stage of the disease. Current treatment of HC can be divided into curative and palliative treatment. For the curative treatment, local excision should only be used on small tumors which are confined to the bile duct wall and Bismuth I papillary carcinoma. Partial hepatectomy should be combined with caudate lobe resection and porta-hepatis lymph node dissection. The results of these major resections can be improved with portal vein embolization, and staging laparoscopy and laparoscopic ultrasound. The role of preoperative biliary drainage is controversial. Autotransplantation for HC gave disappointing results while the Mayo Protocol of chemoradiation for selecting patients with unresectable HC for orthotopic liver transplantation has been widely accepted. Palliative treatment included bypass surgery, endoscopic or percutaneous stenting, photodynamic therapy, intraluminal brachytherapy, and external radiation and systemic therapy. CONCLUSIONS: Adequate surgery with R0 resection should be the main goal of treatment. For patients with unresectable HC, treatment aims to improve the quality and quantity of their survival. | Stephanie Hiu Yan Lau Wan Yee Lau | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，1： | 6 |
| 3 | The current role of radiofrequency ablation in the treatment of hepatocellular carcinoma显示文摘Local ablative therapy is used in treating liver tumors by either injection of cytotoxic agents(chemicals,radioactive isotopes,hyperthermic agents or chemotherapeutic agents)or application of an energy source to achieve thermal ablation,cryoablation or conformal external beam radiation(Table 1). | Wan Yee Lau Stephanie Hiu Yan Lau | 2017 | Hepatobiliary & Pancreatic Diseases International2017，16，2： | 5 |
| 4 | Monocyte-derived Wnt5a regulates inflammatory ymphangiogenesis显示文摘 | Roberto Sessa Don Yuen Stephanie Wan Michael Rosner Preethi Padmanaban Shaokui Ge April Smith Russell Fletcher Ariane Baudhuin-Kessel Terry P Yamaguchi Richard A Lang LuChen | 2016 | Cell Research2016，26，2： | 2 |
| 5 | Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney显示文摘 | STEPHANIE L TRAHAN J WAN W B | 2003 | Antiviral Res2003，59，3： | 1 |
| 6 | The current status of preoperative biliary drainage for patients who receive pancreaticoduodenectomy for periampullary carcinoma: A comprehensive review显示文摘 | Eric C.H. Lai Stephanie H.Y. Lau Wan Yee Lau | 2014 | The Surgeon2014，，： | 1 |
| 7 | Management of bile duct injury after laparoscopic cholecystectomy: a review显示文摘 | Wan YeeLau Eric C. H.Lai Stephanie H. Y.Lau | 2010 | ANZ Journal of Surgery2010，，1： | 1 |
| 8 | Management of bile duct injury after laparoscopic cholecystectomy:a review 显示文摘 | Wan Yee Lau Eric CH Lai Stephanie HY Lau | 2010 | ANZ J Surg2010，80，1： | 1 |
| 9 | Management of bile duet injury after laparoscopic choleeysteetomy: a review 显示文摘 | Wan Yee Lau Eric CH Lai Stephanie HY Lau | 2010 | ANZ J Surg2010，80，1： | 1 |
| 10 | Management of bile duct injury after laparoscopic cholecystectomy: a review显示文摘 | Wan YeeLau Eric C. H.Lai Stephanie H. Y.Lau | 2010 | ANZ Journal of Surgery (鈥?)2010，，1： | 1 |
| 11 | A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum显示文摘Hemoperitoneum 是大意的稀罕、潜在地威胁生活的复杂并发症。我们报导发展了的一个 54 岁的人传播了 intra 腹的复发从一以前 resected 小肠的胃肠的 stromal 瘤(大意) ,和病人与 hemoperitoneum 介绍了。突现的 debulking 外科被执行。高剂量 imatinib 被规定。尽管有剩余疾病的存在,病人临床上好在手术以后的 8 个月。尽管,没有证据在大意的管理支持 debulking 外科的平淡的使用。在我们的病人,在第二根线以后的疾病前进为自发的破裂指向了治疗和其他的治疗选择的缺席, hemoperitoneum 提示了我们好攻击地对待病人。破裂的大意的切除术为流血并且到的控制被执行阻止与好外科的风险的在这个病人的周期性的流血。在治疗期间,决策,病人将军条件,外科的风险和传播的程度被考虑。在与小肠的大意的自发的破裂介绍了的这个病人,指向的治疗和好攻击的外科的治疗的新奇使用生产了相当好的幸存结果。 | Eric C.H. Lai Kam Man Chung Stephanie H.Y. Lau Wan Yee Lau | 2015 | Frontiers of Medicine2015，9，1： | 1 |
| 12 | 脂肪移植的研究:V部分,能提高脂肪移植成活量的辅助细胞脂肪移植是有剂量依赖性的显示文摘背景辅助细胞脂肪移植能提高脂肪移植的成活量。但能显著提高脂肪保留量的基质血管细胞群最佳浓度尚未得知。方法将获得的一部分脂肪待移植,另一部分提取基质血管细胞群。然后将提取出的不同浓度细胞(每200μl的脂肪含有1×10^4-1X10^7个细胞)与脂肪混合进行移植。移植后第8周,通过计算机断层扫描测定脂肪移植的成活量,并将移植的脂肪取出,比较结构和血管的组织学改变。结果加入的细胞浓度为每200μl脂肪含有1×10^4个细胞时,脂肪移植的成活量最大。加入的细胞量过多对脂肪移植的存活是不利的,加入1×10’个细胞时,脂肪的成活量最低,甚至比单纯脂肪移植更低。有趣的是,加入1×10^4个细胞时,血管化明显增加,炎症反应降低;而加入1×10^7个细胞与单纯脂肪移植相比,发生明显脂肪变性。结论我们的研究表明,可加入适量的基质血管细胞群以提高脂肪移植的成活量。虽然辅助细胞脂肪移植能促进移植脂肪的存活,但加入的细胞后期会与脂肪细胞争夺养分,因此,加人的细胞数量与其代谢要平衡。 | KevinJ.Paik Elizabeth R. Zielins David A. Atashroo Zeshaan N. Maan Dominik Duscher Anna Luan Graham G. Walmsley Arash Momeni Stephanie Vistnes Geoffrey C. Gurtner Michael T. Longaker Derrick C. Wan 叶美辰 高景恒 张晨 袁继龙 | 2015 | 中国美容整形外科杂志2015，26，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员